Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia [Phase 3]
Phase 3 trial comparing dasatinib and nilotinib in treatment-naïve chronic myeloid leukemia (chronic phase) has been terminated.
-
CLINICAL_TRIALS trial_result · 2019-01-18Clinical Trial Update: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating inducible regulatory T cells (iTregs) in non-myeloablative sibling donor peripheral blood stem cell transplantation…
-
FDA approval · 2019-01-17FDA Approved: IMATINIB MESYLATE — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' imatinib mesylate as an original application for a generic version of the cancer drug, for the same indica…
-
FDA approval · 2019-01-17FDA Approved: IMATINIB MESYLATE — Original Application (Chartwell RX, LLC)
FDA approves an original ANDA for imatinib mesylate, granting Chartwell RX, LLC a generic version (ANDA 208429).
-
CLINICAL_TRIALS trial_result · 2019-01-17Clinical Trial Update: A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia [Phase 1]
A Phase 1B study evaluating safety and preliminary efficacy of Dasatinib in combination with Nivolumab in Chronic Myeloid Leukemia has been …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-01-14Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) [Phase 1, Phase 2]
A two-phase study evaluating subcutaneous omacetaxine in fixed dose for chronic phase or accelerated phase chronic myeloid leukemia has been…
-
CLINICAL_TRIALS trial_result · 2019-01-09Clinical Trial Update: Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia [Phase 2]
Phase 2 trial investigating pioglitazone in combination with a tyrosine kinase inhibitor for relapsed chronic myeloid leukemia (BCR-ABL1 pos…
-
CLINICAL_TRIALS trial_result · 2019-01-04Clinical Trial Update: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
Phase 2 results from a study using donor umbilical cord blood stem cell transplants in patients with hematologic malignancies have been post…
-
FDA approval · 2018-12-21FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories.
-
FDA approval · 2018-11-15FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2018-11-14Clinical Trial Update: A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Phase 3]
Phase 3 trial comparing bosutinib to imatinib in newly diagnosed chronic phase CML; study completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-11-13Clinical Trial Update: Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI [Phase 2]
A Phase 2 clinical trial comparing interferon and GM-CSF with imatinib mesylate and vaccine therapy in chronic phase CML patients on a TKI h…
-
CLINICAL_TRIALS trial_result · 2018-11-02Clinical Trial Update: Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia [Phase 2]
Phase 2 trial investigating sequences of dasatinib or nilotinib followed by imatinib in newly diagnosed chronic phase chronic myeloid leukem…
-
CLINICAL_TRIALS trial_result · 2018-11-02Clinical Trial Update: Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response [Phase 2]
A Phase 2 open-label study evaluating stopping dasatinib in patients with chronic phase chronic myeloid leukemia who have stable complete mo…
-
CLINICAL_TRIALS trial_result · 2018-10-31Clinical Trial Update: Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]
A nonmyeloablative preparative regimen using Mylotarg (gemtuzumab ozogamicin) was studied in Phase 2/Phase 3 trials for high-risk acute myel…
-
CLINICAL_TRIALS trial_result · 2018-10-30Clinical Trial Update: Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) [Phase 2]
Phase II trial update for SCH66336 (a farnesyltransferase inhibitor) in chronic myelogenous leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C [Phase 2]
Phase 2 trial of higher-dose Gleevec (imatinib), alpha interferon, and low-dose cytarabine for early chronic phase chronic myeloid leukemia …
-
CLINICAL_TRIALS trial_result · 2018-10-02Clinical Trial Update: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study [Phase 1, Phase 2]
A Phase I/II safety and toxicity study of WT1 TCR gene therapy for acute myeloid leukemia and chronic myeloid leukemia has completed.
-
FDA approval · 2018-09-28FDA Approved: BUSULFEX — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approved a supplemental application for Busultex (busulfan) filed by Otsuka America Pharmaceutical, Inc. The action updates the labeling…
-
CLINICAL_TRIALS trial_result · 2018-09-26Clinical Trial Update: Experimental Bone Marrow Transplant Protocol [Phase 2]
Phase 2 clinical trial update for an experimental bone marrow transplant protocol that investigated treatment in blood cancer conditions; st…
-
CLINICAL_TRIALS trial_result · 2018-09-13Clinical Trial Update: A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
A completed observational trial describing real-world use of bosutinib in the UK and Netherlands for chronic myeloid leukemia, with results …
-
CLINICAL_TRIALS trial_result · 2018-08-28Clinical Trial Update: Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia [Phase 2]
Phase 2 clinical trial update for a vaccine therapy in Philadelphia chromosome-positive chronic myeloid leukemia (CML) completed; results po…
-
FDA approval · 2018-08-13FDA Approved: IMATINIB — Original Application (Dr.Reddy's Laboratories Inc)
FDA approved the original application for imatinib from Dr. Reddy's Laboratories Inc, enabling the generic product to be marketed in the Uni…
-
CLINICAL_TRIALS trial_result · 2018-08-06Clinical Trial Update: Nilotinib in PH+, BCR-, ABL+ CML Patients [Phase 3]
Phase 3 clinical trial update for nilotinib in Philadelphia-positive, BCR-ABL-positive chronic myeloid leukemia patients, completed.
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 clinical trial update evaluating nilotinib for newly diagnosed chronic phase chronic myeloid leukemia.